Abstracts tagged "Biologicals"

Abstract Number: 1045 • ACR Convergence 2020
Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.
Inigo Gonzalez-Mazon¹, Alba Herrero Morant², Lara Sanchez-Bilbao², David Martinez-Lopez³, Vanesa Calvo-Río⁴, Carmen Alvarez-Reguera², Santos Castañeda⁵, Esther Francisca Vicente-Rabaneda⁶, Rosalia Demetrio-Pablo², Ana Urruticoechea-Arana⁷, J. L. García-Serrano⁸, J. L. Callejas-Rubio⁸, Norberto Ortego⁸, José Luis Martín-Varillas⁹, Olga Maiz Alonso¹⁰, Ana Blanco¹¹, Francisco Javier Narváez¹², Susana Romero-Yuste¹³, Iñigo Rúa-Figueroa¹⁴, Paula Estrada¹⁵, Julio Sanchez¹⁶, Miguel Ángel González-Gay¹⁷ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁴H.U. Marques de Valdecilla, Santander, Spain, ⁵Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ⁷HOSPITAL CAN MISSES EIVISSA, Ibiza, Spain, ⁸Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹¹Hospital Universitario Donostia, San Sebastian, Spain, ¹²Hospital Bellvitge, BARCELONA, Spain, ¹³H Pontevedra, Coruna, Spain, ¹⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Hospital 12 Octubre, Madrid, Spain, ¹⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Optic Neuritis (ON) is an inflammation of the optic nerve. Its most common presentation is demyelinating typical ON. Atypical ON is rare, severe, non-demyelinating…
Abstract Number: 1353 • ACR Convergence 2020
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage
Laura Coates¹, Désirée van der Heijde², Lars Erik Kristensen³, William Tillett⁴, Jason Eells⁵, Tommi Nurminen⁶ and Atul Deodhar⁷, ¹University of Oxford, Oxford, United Kingdom, ²Leiden University Medical Center, Leiden, Netherlands, ³The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Pre-existing structural damage in patients with psoriatic arthritis (PsA) has been suggested to impact therapeutic improvements in disease activity and functional outcomes.1,2 Here we…
Abstract Number: 1575 • ACR Convergence 2020
CD6 Is a Target for Cancer Immunotherapy
Jeffrey Ruth¹, Mikel Gurrea Rubio², Kalana Athukorala³, Stephanie Rasmussen¹, Weber Daniel¹, Peggy Randon¹, M Asif Amin¹, Phillip Campbell¹, Pei-suen Tsou¹, Yang Mao-Draayer¹, Qi Wu⁴, Matthew Lind¹, Rosemary Gedert¹, Thomas Lanigan¹, Venkateshwar Keshamouni¹, Nora Singer⁵, Feng Lin⁶ and David Fox⁷, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³University of Michigan, Ann Arbor, MN, ⁴University of Michigan, Ann Arbor, ⁵The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed…
Abstract Number: 1991 • ACR Convergence 2020
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq², Mary Buckley³, Kathryn Torok⁴, Barbara Edelheit⁵, Kaleo Ede⁶, Christopher Liu⁷ and C. Egla Rabinovich⁸, ¹Hackensack University Medical Center, Hackensack, ²Montclair State University, Montclair, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Conneticut Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, AZ, ⁷U Pittsburgh, Pittsburgh, ⁸Duke University Hospital, Durham, NC
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 0204 • ACR Convergence 2020
Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects
KyungSang Yu¹, InJin Jang¹, HyeongSeok Lim², JangHee Hong³, MinGul Kim⁴, MinKyu Park⁵, Anhye Kim⁶, MinSoo Park⁷, JaeYong Chung⁸, JongLyul Ghim⁹, SeungHwan Lee¹, SeokKyu Yoon², InSun Kwon³, Daniel Furst*¹⁰, Edward C Keystone¹¹, SangJoon Lee¹², SungHyun Kim¹², YunJu Bae¹², JungBin Cha¹³, HyeJin Kang¹³ and Jonathan Kay¹⁴, ¹Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea, ²College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Republic of Korea, ³Chungnam National University Hospital, Daejeon, Republic of Korea, ⁴College of Medicine, Jeonbuk National University, Jeonbuk, Republic of Korea, ⁵Chungbuk National University Hospital, Cheongju, Republic of Korea, ⁶CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea, ⁷Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁸Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁹Inje University Busan Paik Hospital, Busan, Republic of Korea, ¹⁰Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Celltrion, Inc., Incheon, Republic of Korea, ¹³Celltion, Inc., Incheon, Republic of Korea, ¹⁴University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 was developed as the first biosimilar of the high concentration (100 mg/mL), citrate-free formulation of reference adalimumab. The purpose of this study was…
Abstract Number: 0347 • ACR Convergence 2020
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Proton Rahman¹, Philip Helliwell², Atul Deodhar³, Alexa Kollmeier⁴, Elizabeth Hsia⁵, Bei Zhou⁶, Xiwu Lin⁶, Chenglong Han⁶ and Philip Mease⁷, ¹Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2 are phase-3 trials of guselkumab (GUS, an IL-23 inhibitor) in patients with psoriatic arthritis (PsA). In both trials, treatment with…
Abstract Number: 0447 • ACR Convergence 2020
Magnetic Resonance Imaging Characteristics in Patients with Spondyloarthritis and Clinical Diagnosis of Heel Enthesitis: Screening Data from a Phase 3 Trial
Xenofon Baraliakos¹, Philipp Sewerin², Eugenio De Miguel³, Christine Kleinmond⁴, Ankita Shekhawat⁵, Claudia Jentzsch⁶, Annette Wiedon⁷ and Frank Behrens⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴ClinProject GmbH, Eurasburg, Germany, ⁵Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ⁶Novartis Pharma GmbH, Nuremberg, Germany, ⁷Novartis Pharma GmbH, Nurnberg, Germany, ⁸CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany
Background/Purpose: Inflammation and pain at entheseal sites are the key clinical signs in patients (pts) with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1 Magnetic resonance…
Abstract Number: 0607 • ACR Convergence 2020
The Evolution of Rheumatologist’s Practice in Response to the COVID19 Pandemic
Maria Bacalao¹, Kathryn Dao² and John Cush², ¹UT Southwestern, Dallas, TX, ²University of Texas Southwestern Medical School, Dallas, TX
Background/Purpose: The COVID19 pandemic was a turning point for Rheumatology. This survey of rheumatologists (rheums) assessed its impact on care delivery, patient counseling and drug…
Abstract Number: 0810 • ACR Convergence 2020
Long Term Remission Rates from a Biologic Clinic: 12 Year Real World Data
Kieran Murray¹, Matthew Turk², Yousef Alammari², Francis Young³, Phil Gallagher⁴, Tajvur Saber⁵, Sinead Maguire⁶, Finbar O'Shea⁶, Ursula Fearon⁷ and Douglas Veale⁸, ¹Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin 4, Ireland, ³Saint Vincent's University Hospital, Dublin 4, ⁴St Vincents University Hospital, UCD, Dublin, Ireland, ⁵Peshawar Rheumatology Clinic, Dabgari Garden, Northern Areas, Pakistan, ⁶St James' Hospital, Dublin, Ireland, ⁷Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁸EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Biologic therapies are widely used and greatly improve outcomes in RA and PsA. Yet, our ability to predict long-term remission and persistence remains limited.…
Abstract Number: 0885 • ACR Convergence 2020
Impact of HLA-B27 Status on Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Secukinumab
Atul Deodhar¹, Philip Mease², Denis Poddubnyy³, Vibeke Strand⁴, Paula Machado⁵, Abhijit Shete⁶, Xiangyi Meng⁵ and Marina Magrey⁷, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is strongly associated with the genetic marker HLA-B27. In patients with AS, negative HLA-B27 status is a predictor of worse response…
Abstract Number: 1155 • ACR Convergence 2020
Long-term Safety Profile of Anakinra in Patients with Systemic Juvenile Idiopathic Arthritis
Gabriella Giancane¹, Riccardo Papa¹, Sebastiaan Vastert², Francesca Bagnasco¹, Joost Swart¹, Pierre Quartier³, Jordi Anton⁴, Isabelle Kone Paut¹, Sylvia Kamphuis¹, Troels Herlin⁵, Helga Sanner¹, Fabrizio De Benedetti⁶, Elena Tsitsami⁷, Susan Mary Nielsen¹, Estefania Moreno¹, Chiara Pallotti¹, Karin Franck-Larsson⁸, Håkan Malmström⁸, Susanna Cederholm⁹, Nico Wulffraat¹ and Nicolino Ruperto¹⁰, ¹IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, ²University Medical Center Utrecht, Utrecht, Netherlands, ³Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ⁴Sant Joan de Déu Hospital, Madrid, Spain, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁷Aghia Sophia Childrens Hospital, Athens, Greece, ⁸Swedish Orphan Biovitrum, Stockholm, Sweden, ⁹Sobi, Stockholm, Sweden, ¹⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: To evaluate the long-term safety profile of anakinra in patients with systemic juvenile idiopathic arthritis (sJIA)Methods: Data from patients with sJIA according to the…
Abstract Number: 1358 • ACR Convergence 2020
Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Atul Deodhar¹, Lianne Gensler², Stephen Hall³, Philip Robinson⁴, Bengt Hoepken⁵, Lars Bauer⁵, Thomas Kumke⁵ and Walter Maksymowych⁶, ¹Oregon Health & Science University, Portland, OR, ²University of California San Francisco, San Francisco, CA, ³Cabrini Medical Centre, Monash University and Emeritus Research, Malvern, Victoria, Australia, ⁴University of Queensland, Herston, Queensland, Australia, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: This post-hoc analysis from the phase 3 C-axSpAnd study aimed to evaluate whether the response to certolizumab pegol (CZP) in non-radiographic axial spondyloarthritis (nr-axSpA)…
Abstract Number: 1605 • ACR Convergence 2020
Knowledge of Biosimilars and Perceptions of Biosimilar Naming Conventions in Clinical Practice
Criswell Lavery¹, Marianna Olave², Charles Leonard¹, Vincent Lo Re¹, Jonathan Kay³ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³University of Massachusetts Medical School, Worcester, MA
Background/Purpose: The market introduction of biosimilars has generated the need for novel biologic naming conventions, in part to support pharmacovigilance. We evaluated the familiarity of…
Abstract Number: 2011 • ACR Convergence 2020
Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
Evgeny Nasonov¹, Saeed Fatenejad², Mariana Ivanova³, Diana Krechikova⁴, Sofia Kuzkina⁵, Alexey Maslyanskiy⁶, Tatiana Plaksina⁷, Mikhail Samsonov⁵, Marina Stanislav¹, Tamara Tyabut⁸, Irina Vinogradova⁹, Sergey Yakushin¹⁰, Elena Zonova¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, LLC, Charlotte, NC, ³UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"”, Smolensk, Russia, ⁵JSC “R-Pharm”, Moscow, Russia, ⁶SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov", Saint Petersburg, Russia, ⁷SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", Nizhny Novgorod, Russia, ⁸Belarusian Medical Academy of Postgraduate Education, Minsk, Russia, ⁹Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic, Novosibirsk, Russia, ¹²Stanford University Medical Center, Palo Alto, CA
Background/Purpose: We previously reported positive efficacy and safety results of olokizumab (OKZ), an interleukin-6-inhibitor, in patients with RA inadequately controlled by MTX (NCT02760368; CREDO-1) [Nasonov…
Abstract Number: 0206 • ACR Convergence 2020
Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)
Naoto Tamura¹, Eiichi Tanaka², Eisuke Inoue³, Yuri Yoshizawa⁴, Shigeru Matsumoto⁵, Hisashi Yamanaka⁶ and Masayoshi Harigai⁷, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Bristol-Myers Squibb K.K., Tokyo, Japan, ⁵Ono Pharmaceutical Co., Ltd., Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Rheumatology, Sanno Medical Center, Tokyo, Japan, ⁷Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Long-term clinical benefit and patient-reported outcomes (PRO) of subcutaneously-injected abatacept (ABA) in patients with RA in a real-world setting are of therapeutic interest. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].